For Immediate Release
Chicago, IL –June 25, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Union Pacific (UNP - Free Report) , NextEra (NEE - Free Report) , Biogen (BIIB - Free Report) , Humana (HUM - Free Report) and Marathon Petroleum (MPC - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Union Pacific, NextEra & Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Union Pacific, NextEra and Biogen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Union Pacific’s shares have underperformed the Zacks Rail industry (+22.2% vs. +25.5%) year to date. The Zacks analyst thinks Union Pacific's second-quarter 2019 results, scheduled to be revealed on Jul 18, will be hurt by sluggish freight revenues as was the case in the first quarter.
Declining shipments apart, high operating expenses may prove detrimental to the company. High debt levels are worrisome too. Notably, Debt/EBITDA ratio (adjusted) increased to 2.6 in the first quarter of 2019 from 2.3 at 2018 end. However, the company's efforts to reward its investors through share buybacks and dividend payouts are impressive.
Since November 2017, Union Pacific hiked its quarterly dividend payout four times. The company is also active on the buyback front. Its strategic initiatives toward promoting safety and enhancing productivity represent an additional positive.
(You can read the full research report on Union Pacific here >>>).
Shares of NextEra have outperformed the Zacks Electric Power industry in the past year, gaining +24.7% vs +13.5%. The Zacks analyst thinks NextEra’s investments under the “30 by 30” plan, targeted at strengthening renewable operations, will help the company to continue as a market leader in renewable power generation.
Focus on expanding operations in natural gas pipelines, and further expansion of business through acquisitions and organic growth has positively impacted earnings. However, its nature of business is subject to complex and comprehensive federal, state, and other regulations. Substantial investments are undertaken to ensure the safety of nuclear operations.
That said, if planned outages last longer than expected or there is an unplanned outage, the company’s regular operations and profitability might be hindered.
(You can read the full research report on NextEra here >>>).
Biogen’s shares have declined -20.6% year to date, underperforming the Zacks Outsourcing industry, which has gained +6.3% over the same period. The Zacks analyst likes Biogen’s efforts to diversify beyond MS to other areas like Alzheimer’s, Parkinson's and stroke. Spinraza is performing well and has multi-billion dollar potential.
Biogen’s efforts to regularly in-license assets in order to build its pipeline are commendable since several of them have transformative potential. Several data readouts are expected in 2019/2020 with multiple potential launches in the early 2020s.
However, its core MS business, excluding Ocrevus royalties, is suffering from a declining trend. Also, potential competition to Spinraza from competitors’ gene therapy programs for SMA is a concern. Though Biogen’s CNS pipeline is attractive, it is a high-risk area as evident from the recent failure of Alzheimer’s candidate aducanumab and uncertainty over the future of others like BAN2401.
(You can read the full research report on Biogen here >>>).
Other noteworthy reports we are featuring today include Humana and Marathon Petroleum.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.